Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 448-455

  Dostalek, Miroslav ^a   Court, Michael H ^b   Hazarika, Suwagmani ^b   Akhlaghi, Fatemeh ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MESSENGER RNA; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID ACYLGLUCURONIDE; MYCOPHENOLIC ACID PHENOL GLUCURONIDE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME KINETICS; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; KIDNEY MICROSOME; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; DIABETES MELLITUS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONATES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KINETICS; LIVER; MALE; MICROSOMES; MICROSOMES, LIVER; MIDDLE AGED; MYCOPHENOLIC ACID; RNA, MESSENGER; ZIDOVUDINE;

EID: 79951920970     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036608     Document Type: Article

References (39)

1. Akhlaghi F, Patel CG, Zuniga XP, Halilovic J, Preis IS, and Gohh RY (2006) Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 28:95-101. (Pubitemid 44391701)
2. Barraclough KA, Lee KJ, and Staatz CE (2010) Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 11:369-390.
3. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, and Bélanger A (2000) 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497-502. (Pubitemid 30238507)
4. Basu NK, Kole L, Kubota S, and Owens IS (2004) Human UDP- glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32:768-773. (Pubitemid 38821880)
5. Bernard O and Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778. (Pubitemid 38955603)
6. Bernard O, Tojcic J, Journault K, Perusse L, and Guillemette C (2006) Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 34:1539-1545. (Pubitemid 44285396)
7. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, and Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685.
8. Bowalgaha K and Miners JO (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
9. Bullingham R, Monroe S, Nicholls A, and Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36:315-324. (Pubitemid 26125953)
10. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
11. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133. (Pubitemid 37048284)
12. Engtrakul JJ, Foti RS, Strelevitz TJ, and Fisher MB (2005) Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos 33:1621-1627. (Pubitemid 41539959)
13. Ensom MH, Partovi N, Decarie D, Dumont RJ, Fradet G, and Levy RD (2002) Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit 24:310-314. (Pubitemid 34246559)
14. Ernster L and Nordenbrand K (1967) Microsomal protein peroxidation. Methods Enzymol 10:574-580.
15. Guengerich F and Bartleson C (2001) Analysis and characterization of enzymes and nucleic acids, in: Principles and Methods of Toxicology, 5th ed (Hayes A ed) pp 1625-1687, Taylor & Francis, Philadelphia.
16. Guengerich FP, Wang P, and Davidson NK (1982) Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21:1698-1706. (Pubitemid 12128223)
17. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T, and Suzuki T (2007) Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:279-288. (Pubitemid 46233156)
18. Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, Kashuba AD, and Court MH (2009) Interindividual variability in pharmacokinetics of genetic nucleoside reverse transcriptase inhibitors in TB/HIV-co-infected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 49:1079-1090.
19. Mackenzie PI (2000) Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 22:10-13.
20. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
21. Manevski N, Kurkela M, Höglund C, Mauriala T, Court MH, Yli-Kauhaluoma J, and Finel M (2010) Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos 38:386-395.
22. McGurk KA, Brierley CH, and Burchell B (1998) Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005-1012. (Pubitemid 28167722)
23. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, and Ritter JK (2005) An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 33:1513-1520. (Pubitemid 41324000)
24. Parker G, Bullingham R, Kamm B, and Hale M (1996) Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 36:332-344. (Pubitemid 26125954)
25. Patel CG and Akhlaghi F (2006) High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit 28:116-122. (Pubitemid 44391705)
26. Patel CG, Richman K, Yang D, Yan B, Gohh RY, and Akhlaghi F (2007) Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther Drug Monit 29:735-742. (Pubitemid 350190849)
27. Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, Tomlanovich S, Weinstein S, Inokuchi S, Kiberd B, et al. (2000) Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 14:179-188. (Pubitemid 30242951)
28. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146. (Pubitemid 40023525)
29. Shipkova M, Armstrong VW, Oellerich M, and Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16. (Pubitemid 36139819)
30. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weiss G, Voihsel M, Braun F, and Oellerich M (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126:1075-1082. (Pubitemid 29123740)
31. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Oellerich M, and Wieland E (2000) Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 46:365-372. (Pubitemid 30152262)
32. Shipkova M, Spielbauer B, Voland A, Gröne HJ, Armstrong VW, Oellerich M, and Wieland E (2004) cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation 78:1145-1152. (Pubitemid 39426432)
33. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, and Wieland E (2001) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027-1034. (Pubitemid 32238908)
34. Westley IS, Brogan LR, Morris RG, Evans AM, and Sallustio BC (2006) Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 34:261-266. (Pubitemid 43148995)
35. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, and Oellerich M (2000) Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33:107-113. (Pubitemid 30212818)
36. Wilson DW and Wilson HC (1962) Studies in vitro of the digestion and absorption of purine ribonucleotides by the intestine. J Biol Chem 237:1643-1647.
37. Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, and Min DI (2009) Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit 31:542-548.
38. Yang J, Shi D, Yang D, Song X, and Yan B (2007) Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol 72:686-694. (Pubitemid 47347303)
39. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, and Miller J (1999) Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 21:35-43. (Pubitemid 29077452)